OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

761 Projects | 524 Researchers | $300,400,508 Invested

2023

Metro International Biotech

David Livingston, PhD

  • Funding Amount: $5,750,000
  • Program: Clinical
  • Target: Mitochondria/Metabolic Function
  • Status: Active

2023

ADmit Therapeutics S.L.

Marta Barrachina, PhD, MBA

  • Funding Amount: $1,886,057
  • Program: Biomarkers
  • Target: Mitochondria/Metabolic Function
  • Status: Active

2023

NeuroAge Therapeutics

Christin Glorioso, MD, PhD

  • Funding Amount: $249,817
  • Program: Biomarkers
  • Target: Epigenetics
  • Status: Active

2023

Optina Diagnostics

Jean-Philippe Sylvestre, PEng, PhD

  • Funding Amount: $1,523,500
  • Program: Biomarkers
  • Target: Other
  • Status: Active

2023

Virginia Commonwealth University

Shijun Zhang, PhD

  • Funding Amount: $600,000
  • Program: Biomarkers
  • Target: Neuroinflammation
  • Status: Active

2023

Genuv Inc.

Sungho HAN

  • Funding Amount: $600,000
  • Program: Drug Discovery
  • Target: Neuronal Regeneration and Repair
  • Status: Active

2023

GliaPharm SA

Pierre Magistretti, MD, PhD

  • Funding Amount: $4,262,019
  • Program: Drug Discovery
  • Target: Mitochondria/Metabolic Function
  • Status: Active

2023

Amprion Inc

Russell Lebovitz, MD PhD

  • Funding Amount: $570,750
  • Program: Biomarkers
  • Target: Proteostasis
  • Status: Active

2023

TUFTS Medical Center

David Kent, MD, MS

  • Funding Amount: $599,788
  • Program: Biomarkers
  • Target: Vascular
  • Status: Active

2023

Imeka

Maxime Descoteaux, PhD

  • Funding Amount: $815,393
  • Program: Biomarkers
  • Target: Neuroinflammation
  • Status: Active